Corcept Therapeutics (CORT) Earnings Date & Reports

Key Takeaways

• Analysts expect Q1 2026 revenue of $186.61 million, reflecting approximately 19% year-over-year growth from $157.2 million in Q1 2025.
• Consensus EPS estimate stands at -$0.14, driven by elevated R&D (research and development) spending on pipeline candidates.
• Full-year 2026 revenue guidance of $900–$1,000 million underscores sustained Korlym demand and market expansion.
• Key focus areas include updates on relacorilant trials and new patient starts for Korlym.
• February 2026 marked a record for new Cushing's syndrome patients initiating treatment.
• Investors anticipate commentary on NDA (New Drug Application) progress for relacorilant in Cushing's syndrome.

Earnings Context and Why It Matters

Corcept Therapeutics, a biopharmaceutical company targeting disorders linked to excess cortisol activity, relies heavily on its flagship drug Korlym for revenue from Cushing's syndrome treatment. The upcoming Q1 2026 earnings, expected around May 4, carry weight amid accelerating revenue trends—full-year 2025 hit $761.4 million, up from $675 million prior year—fueled by growing patient access. Investors are watching for sustained momentum against a backdrop of rising R&D costs for pipeline assets like relacorilant. This report could signal execution on 2026 guidance and influence sentiment in the competitive endocrinology space, where demand signals and regulatory milestones drive valuations.

Earnings Expectations

Wall Street anticipates Q1 2026 revenue of $186.61 million, a 18.7% increase from Q1 2025's $157.2 million, propelled by Korlym's expanding prescriptions. EPS consensus is -$0.14 per share (based on five analysts), pressured by investments in clinical programs.

Past performance shows revenue beats but EPS variability; Q4 2025 revenue reached $202.1 million (up 11% YoY) though EPS of $0.20 missed estimates. The company guides FY2026 revenue to $900–$1,000 million, implying quarterly ramps. Metrics to monitor include new patient adds, cash burn (end-2025 cash: $532.4 million), and updates on relacorilant, including Cushing's NDA confidence and July 11 PDUFA (FDA Prescription Drug User Fee Act target action date) for ovarian cancer.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your analysis of biotech names like CORT.

Market Reaction and Investor Sentiment

Heading into Q1 earnings, sentiment leans cautiously optimistic, buoyed by Q4's revenue growth and robust FY2026 guidance despite the EPS miss. CORT shares have shown resilience, trading amid pipeline enthusiasm. Risks include pharmacy disruptions or slower-than-expected patient onboarding, which impacted prior quarters. Historically, beats on revenue have spurred gains, while guidance reaffirmations stabilize volatility.

Forward Outlook and Key Factors to Monitor

Post-earnings, attention will shift to management's confirmation of FY2026 revenue trajectory amid Korlym's market penetration. February's record new patient starts signal durable demand in Cushing's syndrome, but sustaining quarterly growth toward $900–$1,000 million requires monitoring payer dynamics and competition.

Pipeline catalysts loom large: relacorilant NDA for Cushing's syndrome (with FDA interactions ongoing) and PDUFA July 11 for platinum-resistant ovarian cancer. Additional 2026 data readouts—MOMENTUM topline in March, BELLA and MONARCH by year-end—could validate expansion beyond Korlym.

Balance sheet strength ($532 million cash) supports R&D, but margin pressures from operating expenses (up in recent quarters) warrant scrutiny. Broader industry trends, like cortisol modulator adoption, will shape long-term prospects. Investors should track quarterly patient metrics and regulatory filings for directional cues.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations